Best JH - Search Results

1

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis.

Best JH, Kong AM, Smith DM, Abbass I, Michalska M. Best JH, et al. Clinicoecon Outcomes Res. 2019 Dec 23;11:799-807. doi: 10.2147/CEOR.S228400. eCollection 2019. Clinicoecon Outcomes Res. 2019. PMID: 31920351 Free PMC article.

2

Estimating the Cost of Illness of Giant Cell Arteritis in the United States.

Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP Jr. Babigumira JB, et al. Among authors: best jh. Rheumatol Ther. 2017 Jun;4(1):111-119. doi: 10.1007/s40744-017-0052-8. Epub 2017 Jan 13. Rheumatol Ther. 2017. PMID: 28084585 Free PMC article.

3

Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis.

Best JH, Kong AM, Lenhart GM, Sarsour K, Stott-Miller M, Hwang Y. Best JH, et al. J Rheumatol. 2018 Mar;45(3):320-328. doi: 10.3899/jrheum.170418. Epub 2018 Jan 15. J Rheumatol. 2018. PMID: 29335343

4

Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States.

Kong AM, Kim G, Michalska M, Best JH. Kong AM, et al. Among authors: best jh. Rheumatol Ther. 2018 Jun;5(1):159-170. doi: 10.1007/s40744-018-0099-1. Epub 2018 Feb 22. Rheumatol Ther. 2018. PMID: 29470835 Free PMC article.

5

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data.

Gale S, Trinh H, Tuckwell K, Collinson N, Stone JH, Sarsour K, Pei J, Best J, Birchwood C, Mohan SV. Gale S, et al. Among authors: best j. Rheumatol Ther. 2019 Mar;6(1):77-88. doi: 10.1007/s40744-019-0139-5. Epub 2019 Feb 1. Rheumatol Ther. 2019. PMID: 30707391 Free PMC article.

6

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database.

Best JH, Kong AM, Unizony S, Tran O, Michalska M. Best JH, et al. Rheumatol Ther. 2019 Dec;6(4):599-610. doi: 10.1007/s40744-019-00180-9. Epub 2019 Oct 26. Rheumatol Ther. 2019. PMID: 31656021 Free PMC article.

7

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.

Best JH, Vlad SC, Tominna L, Abbass I. Best JH, et al. Rheumatol Ther. 2020 Jun;7(2):345-355. doi: 10.1007/s40744-020-00201-y. Epub 2020 Mar 29. Rheumatol Ther. 2020. PMID: 32227284 Free PMC article.

8

Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis.

Best JH, Abbass I, Tominna L, Reiss W. Best JH, et al. Am Health Drug Benefits. 2020 May;13(2):72-73. Am Health Drug Benefits. 2020. PMID: 32724501 Free PMC article. No abstract available.

9

Baseline Demographics and Clinical Characteristics Among 3471 US Patients Hospitalized with COVID-19 and Pulmonary Involvement: A Retrospective Study.

Best JH, Mohan SV, Kong AM, Patel K, Pagel JM, Ivanov B, Brawley OW, Jariwala-Parikh K, Zazzali JL, Pauk J. Best JH, et al. Adv Ther. 2020 Dec;37(12):4981-4995. doi: 10.1007/s12325-020-01510-y. Epub 2020 Oct 12. Adv Ther. 2020. PMID: 33044691 Free PMC article.

10

Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.

Best JH, Kong AM, Kaplan-Lewis E, Brawley OW, Baden R, Zazzali JL, Miller KS, Loveless J, Jariwala-Parikh K, Mohan SV. Best JH, et al. J Med Virol. 2021 Sep;93(9):5367-5375. doi: 10.1002/jmv.27049. Epub 2021 May 31. J Med Virol. 2021. PMID: 33913536 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters